AI + biobank
Introduce the human
The high failure rate in oncology drug development trials hints at a lack of drug-response data in a heterogeneous tumor population. This can impact even the most confident drug-discovery design. But what if you could introduce this valuable data well before clinical trials? With PEDAL you can. Our AI-driven platform is powered by a biobank of tumor samples to move molecules forward with a higher probability of success.
Artificial intelligence meets human diversity
While other AI companies purport to help speed and optimize the drug discovery process, PEDAL offers something never before seen in this industry: tumor features drived from a biobank of over 150,000 tumor samples from 137 cancer types.
Start a PEDAL pilot program today
Complete the form and our PEDAL expert will be in touch to discuss customized solutions for your needs.